arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2024-2455AEKLUBarthyper-2455Research ArticleСтатьиArticlesФактор роста фибробластов 21: новое звено в развитии и коррекции метаболических нарушенийFibroblast growth factor 21: a novel link in the development and treatment of metabolic disordershttps://orcid.org/0000-0001-6066-3525МихайловаА. А.MikhailovaA. A.

Михайлова Арина Алексеевна—врач-эндокринолог, младший научный сотрудник научно-исследовательской лаборатории новой коронавирусной инфекции и постковидного синдрома НЦМУ «Центр персонализированной медицины», аспирант кафедры эндокринологии

ул. Аккуратова, д.2, Санкт-Петербург, 197341

Arina A. Mikhailova, MD, Endocrinologist, Junior Researcher, Research Laboratory of new Coronavirus Infection and Postcovid Syndrome, World-Class Research “Centre for Personalized Medicine”, Postgraduate Student, Department of Endocrinology

2 Akkuratov str., St Petersburg, 197341

armikhaylova@yandex.ruШарыповаМ. В.SharypovaM. V.

Шарыпова Марина Валерьевна—лаборант-исследователь научно-исследовательской лаборатории новой коронавирусной инфекции и постковидного синдрома НЦМУ «Центр персонализированной медицины»

ул. Аккуратова, д.2, Санкт-Петербург, 197341

Marina V. Sharypova, MD, Laboratory Assistant Researcher, Research Laboratory of new Coronavirus Infection and Postcovid Syndrome, World-Class Research “Centre for Personalized Medicine”

2 Akkuratov str., St Petersburg, 197341

sharypova186@gmail.comhttps://orcid.org/0000-0003-3300-1280СиманенковаА. В.SimanenkovaA. V.

Симаненкова Анна Владимировна — кандидат медицинских наук, старший научный сотрудник научно-исследовательской лаборатории клинической эндокринологии Института эндокринологии, ассистент кафедры факультетской терапии Института медицинского образования

ул. Аккуратова, д.2, Санкт-Петербург, 197341

Anna V. Simanenkova, MD, PhD, Senior Researcher, Research Laboratory of Clinical Endocrinology of the Institute of Endocrinology, Assistant, Department of Faculty Therapy at the Institute of Medical Education

2 Akkuratov str., St Petersburg, 197341

annasimanenkova@mail.ruhttps://orcid.org/0000-0002-1896-5703ЧебуркинЮ. В.CheburkinYu. V.

Чебуркин Юрий Владимирович — кандидат медицинских наук, научный сотрудник научно-исследовательской лаборатории нейрогенеза и нейродегенеративных заболеваний, заведующий научно-исследовательской лабораторией инфекционных патогенов и биомолекулярных наноструктур НЦМУ «Центр персонализированной медицины»

ул. Аккуратова, д.2, Санкт-Петербург, 197341

Yuri V. Cheburkin, MD, PhD, Researcher, Research Laboratory of Neurogenesis and Neurodegenerative Diseases, Head, Research Laboratory of Infectious Pathogens and Biomolecular Nanostructures, World-Class Research “Centre for Personalized Medicine”

2 Akkuratov str., St Petersburg, 197341

cheburkin_yuv@almazovcentre.ruhttps://orcid.org/0000-0003-0112-5027ФуксО. С.FuksO. S.

Фукс Оксана Станиславовна — лаборант-исследователь научно-исследовательской лаборатории новой коронавирусной инфекции и пост-ковидного синдрома Научного центра мирового уровня «Центр персонализированной медицины»

ул. Аккуратова, д.2, Санкт-Петербург, 197341

Oksana S. Fuks, MD, Research Assistant, Laboratory of Novel Coronavirus Infection and Post-COVID Syndrome, World-Class Research Centre for Personalized Medicine

2 Akkuratov str., St Petersburg, 197341

fuks_os@mail.ruhttps://orcid.org/0000-0001-9836-5427ТимкинаН. В.TimkinaN. V.

Тимкина Наталья Владимировна—младший научный сотрудник научно-исследовательской лаборатории клинической эндокринологии

ул. Аккуратова, д.2, Санкт-Петербург, 197341

Natalya V. Timkina, MD, Junior Researcher, Laboratory of Clinical Endocrinology

2 Akkuratov str., St Petersburg, 197341

n.timkina2014@yandex.ruhttps://orcid.org/0000-0001-8100-7367ДячукВ. А.DyachukV. A.

Дячук Вячеслав Алексеевич — кандидат биологических наук, ведущий научный сотрудник, заведующий научно-исследовательской лабораторией нейрогенеза и нейродегенеративных заболеваний НЦМУ «Центр персонализированной медицины»

ул. Аккуратова, д.2, Санкт-Петербург, 197341

Vyacheslav A. Dyachuk, Candidate of Biological Sciences, Leading Researcher, Head, Research Laboratory of Neurogenesis and Neurodegenerative Diseases, World-Class Research “Centre for Personalized Medicine”

2 Akkuratov str., St Petersburg, 197341

dyachuk_va@almazovcentre.ruhttps://orcid.org/0000-0002-1547-0123КароноваТ. Л.KaronovaT. L.

Каронова Татьяна Леонидовна—доктор медицинских наук, заведующая научно-исследовательской лабораторией новой коронавирусной инфекции и постковидного синдрома НЦМУ «Центр персонализированной медицины», главный научный сотрудник научно-исследовательской лаборатории клинической эндокринологии  Института эндокринологии, профессор кафедры эндокринологии Института  медицинского образования 

ул. Аккуратова, д.2, Санкт-Петербург, 197341

Tatiana L. Karonova, MD, PhD, DSc, Head, Research Laboratory of New Coronavirus infection and Postcovid syndrome, World-Class Research “Centre for Personalized Medicine”, Chief Researcher, Research Laboratory of Clinical Endocrinology, Institute of Endocrinology, Professor, Department of Endocrinology, Institute of Medical Education

2 Akkuratov str., St Petersburg, 197341

karonova@mail.ruФедеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени В.А.Алмазова» Министерства здравоохранения Российской ФедерацииРоссияAlmazov National Medical Research CentreRussian FederationФедеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени В.А.Алмазова» Министерства здравоохранения Российской ФедерацииРоссияAlmazov National Medical Research CentreRussian Federation202421012025305441450Copyright © Михайлова А.А., Шарыпова М.В., Симаненкова А.В., Чебуркин Ю.В., Фукс О.С., Тимкина Н.В., Дячук В.А., Каронова Т.Л., 20252025Михайлова А.А., Шарыпова М.В., Симаненкова А.В., Чебуркин Ю.В., Фукс О.С., Тимкина Н.В., Дячук В.А., Каронова Т.Л.Mikhailova A.A., Sharypova M.V., Simanenkova A.V., Cheburkin Y.V., Fuks O.S., Timkina N.V., Dyachuk V.A., Karonova T.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/2455

В последние годы фактор роста фибробластов 21 (fibroblast growth factor 21, FGF21) привлекает все большее научное внимание как метаболический регулятор. Он участвует в формировании чувствительности тканей к инсулину, оказывает благоприятное влияние на углеводный и липидный обмен, а также обладает антигипергликемическими и гиполипидемическими свойствами. Повышение уровня FGF21 выявлено у пациентов с сахарным диабетом 2го типа, ожирением, неалкогольной жировой болезнью печени и рядом других заболеваний. Это может свидетельствовать как о резистентности к FGF21, так и о компенсаторном ответе на метаболический стресс. Результаты проведенных исследований свидетельствуют о том, что FGF21 может рассматриваться как маркер ряда метаболических нарушений, а также как потенциальный лекарственный препарат для лечения социально значимых заболеваний. Цель данного обзора — обобщить данные, посвященные изучению диагностической и потенциальной терапевтической роли FGF21 в отношении метаболических нарушений.

In recent years, fibroblast growth factor 21 (FGF21) has garnered increasing attention as a metabolic regulator. It plays a role in the development of tissue insulin sensitivity, exerts beneficial effects on carbohydrate and lipid metabolism, and exhibits antihyperglycemic and antilipidemic properties. Elevated FGF21 levels have been observed in patients with type 2 diabetes, obesity, non-alcoholic fatty liver disease, and a range of other conditions. This may indicate either resistance to FGF21 or a compensatory response to metabolic stress. Evidence suggests that FGF21 can be considered both a marker of several metabolic disorders and a potential therapeutic agent for the treatment of significant societal health issues. Objective. The objective of this review is to summarize the data published to date in the literature, including meta-analyses, reviews, and original studies, focusing on the diagnostic and potential therapeutic role of FGF21 in metabolic disorders.

фактор роста фибробластов 21FGF 21ожирениенеалкогольная жировая болезнь печенисахарный диабет 2 типасердечно-сосудистые заболеванияметаболические нарушенияfibroblast growth factor 21FGF21obesitynon-alcoholic fatty liver diseasetype 2 diabetescardiovascular diseasemetabolic disordersИсследование выполнено при финансовой поддержке Министерства науки и высшего образования Российской Федерации (Соглашение № 075–15–2022–301 от 20.04.2022).The research was carried out with the financial support of the Ministry of Science and Higher Education of the Russian Federation (Agreement No. 075–15–2022– 301 dated 20.04.2022).ReferencesCuevas-Ramos D, Aguilar-Salinas CA, Gómez-Pérez FJ. Metabolic actions of fibroblast growth factor 21. Curr Opin Pediatr. 2012;24(4):523–529. doi:10.1097/MOP.0b013e3283557d22Cuevas-Ramos D, Aguilar-Salinas CA, Gómez-Pérez FJ. Metabolic actions of fibroblast growth factor 21. Curr Opin Pediatr. 2012;24(4):523–529. doi:10.1097/MOP.0b013e3283557d22Chen Z, Yang L, Liu Y, Huang P, Song H, ZhengP.The potential function and clinical application of FGF21 in metabolic diseases. Front Pharmacol. 2022;13:1089214. doi:10.3389/fphar.2022.1089214Chen Z, Yang L, Liu Y, Huang P, Song H, ZhengP.The potential function and clinical application of FGF21 in metabolic diseases. Front Pharmacol. 2022;13:1089214. doi:10.3389/fphar.2022.1089214Nishimura T, Nakatake Y, Konishi M, ItohN.Identification of a novel FGF, FGF21, preferentially expressed in the liver. Biochim Biophys Acta. 2000;1492(1):203–206. doi:10.1016/s0167-4781(00)00067-1Nishimura T, Nakatake Y, Konishi M, ItohN.Identification of a novel FGF, FGF21, preferentially expressed in the liver. Biochim Biophys Acta. 2000;1492(1):203–206. doi:10.1016/s0167-4781(00)00067-1Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-FlierE.Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 2007;5(6):426–437. doi:10.1016/j.cmet.2007.05.002Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-FlierE.Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 2007;5(6):426–437. doi:10.1016/j.cmet.2007.05.002Berglund ED, Kang L, Lee-Young RS, Hasenour CM, Lustig DG, Lynes SE et al. Glucagon and lipid interactions in the regulation of hepatic AMPK signaling and expression of PPARα and FGF21 transcripts in vivo. Am J Physiol Endocrinol Metab. 2010;299(4):E607–E614. doi:10.1152/ajpendo.00263.2010Berglund ED, Kang L, Lee-Young RS, Hasenour CM, Lustig DG, Lynes SE et al. Glucagon and lipid interactions in the regulation of hepatic AMPK signaling and expression of PPARα and FGF21 transcripts in vivo. Am J Physiol Endocrinol Metab. 2010;299(4):E607–E614. doi:10.1152/ajpendo.00263.2010Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ et al. FGF21 as a novel metabolic regulator. J Clin Invest. 2005;115(6):1627–1635. doi:10.1172/JCI23606Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ et al. FGF21 as a novel metabolic regulator. J Clin Invest. 2005;115(6):1627–1635. doi:10.1172/JCI23606Spann RA, Morrison CD, den Hartigh LJ. The nuanced metabolic functions of endogenous FGF21 depend on the nature of the stimulus, tissue source, and experimental model. Front Endocrinol (Lausanne). 2022;12:802541. doi:10.3389/fendo.2021.802541Spann RA, Morrison CD, den Hartigh LJ. The nuanced metabolic functions of endogenous FGF21 depend on the nature of the stimulus, tissue source, and experimental model. Front Endocrinol (Lausanne). 2022;12:802541. doi:10.3389/fendo.2021.802541Tezze C, Romanello V, SandriM. FGF21 as modulator of metabolism in health and disease. Front Physiol. 2019;10:419. doi:10.3389/fphys.2019.00419Tezze C, Romanello V, SandriM. FGF21 as modulator of metabolism in health and disease. Front Physiol. 2019;10:419. doi:10.3389/fphys.2019.00419Li S, Chen J, Wei P, Zou T, YouJ.Fibroblast growth factor 21: a fascinating perspective on the regulation of muscle metabolism. Int J Mol Sci. 2023;24(23):16951. doi:10.3390/ijms242316951Li S, Chen J, Wei P, Zou T, YouJ.Fibroblast growth factor 21: a fascinating perspective on the regulation of muscle metabolism. Int J Mol Sci. 2023;24(23):16951. doi:10.3390/ijms242316951Kaur N, Gare SR, Shen J, Raja R, Fonseka O, LiuW.Multiorgan FGF21-FGFR1 signaling in metabolic health and disease. Front Cardiovasc Med. 2022;9:962561. doi:10.3389/fcvm.2022.962561Kaur N, Gare SR, Shen J, Raja R, Fonseka O, LiuW.Multiorgan FGF21-FGFR1 signaling in metabolic health and disease. Front Cardiovasc Med. 2022;9:962561. doi:10.3389/fcvm.2022.962561Pan Y, Wang B, Zheng J, Xiong R, Fan Z, Ye Y et al. Pancreatic fibroblast growth factor 21 protects against type 2 diabetes in mice by promoting insulin expression and secretion in a PI3K/Akt signaling-dependent manner. J Cell Mol Med. 2019;23(2):1059–1071. doi:10.1111/jcmm.14007Pan Y, Wang B, Zheng J, Xiong R, Fan Z, Ye Y et al. Pancreatic fibroblast growth factor 21 protects against type 2 diabetes in mice by promoting insulin expression and secretion in a PI3K/Akt signaling-dependent manner. J Cell Mol Med. 2019;23(2):1059–1071. doi:10.1111/jcmm.14007Klein Hazebroek M, KeipertS.Adapting to the cold: a role for endogenous fibroblast growth factor 21 in thermoregulation? Front Endocrinol (Lausanne). 2020;11:389. doi:10.3389/fendo.2020.00389Klein Hazebroek M, KeipertS.Adapting to the cold: a role for endogenous fibroblast growth factor 21 in thermoregulation? Front Endocrinol (Lausanne). 2020;11:389. doi:10.3389/fendo.2020.00389BonDurant LD, Ameka M, Naber MC, Markan KR, Idiga SO, Acevedo MR et al. FGF21 Regulates metabolism through adipose-dependent and independent mechanisms. Cell Metab. 2017;25(4):935–44.e4. doi:10.1016/j.cmet.2017.03.005BonDurant LD, Ameka M, Naber MC, Markan KR, Idiga SO, Acevedo MR et al. FGF21 Regulates metabolism through adipose-dependent and independent mechanisms. Cell Metab. 2017;25(4):935–44.e4. doi:10.1016/j.cmet.2017.03.005Suzuki M, Uehara Y, Motomura-Matsuzaka K, Oki J, Koyama Y, Kimura M et al. betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol Endocrinol. 2008;22(4):1006–1014. doi:10.1210/me.2007-0313Suzuki M, Uehara Y, Motomura-Matsuzaka K, Oki J, Koyama Y, Kimura M et al. betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol Endocrinol. 2008;22(4):1006–1014. doi:10.1210/me.2007-0313Geng L, Liao B, Jin L, Yu J, Zhao X, Zhao Y et al. β-Klotho promotes glycolysis and glucose-stimulated insulin secretion via GP130. Nat Metab. 2022;4(5):608–626. doi:10.1038/s42255-022-00572-2Geng L, Liao B, Jin L, Yu J, Zhao X, Zhao Y et al. β-Klotho promotes glycolysis and glucose-stimulated insulin secretion via GP130. Nat Metab. 2022;4(5):608–626. doi:10.1038/s42255-022-00572-2Villarroya F, Cereijo R, Villarroya J, Giralt M.Brown adipose tissue as a secretory organ. Nat Rev Endocrinol. 2017;13(1):26–35. doi:10.1038/nrendo.2016.136Villarroya F, Cereijo R, Villarroya J, Giralt M.Brown adipose tissue as a secretory organ. Nat Rev Endocrinol. 2017;13(1):26–35. doi:10.1038/nrendo.2016.136Flippo KH, Potthoff MJ. Metabolic messengers: FGF21. Nat Metab. 2021;3(3):309–317. doi:10.1038/s42255-021-00354-2Flippo KH, Potthoff MJ. Metabolic messengers: FGF21. Nat Metab. 2021;3(3):309–317. doi:10.1038/s42255-021-00354-2Liu Y, Liu Y, Deng J, Li W, Nie X. Fibroblast growth factor in diabetic foot ulcer: progress and therapeutic prospects. Front Endocrinol (Lausanne). 2021;12:744868. doi:10.3389/fendo.2021.744868Liu Y, Liu Y, Deng J, Li W, Nie X. Fibroblast growth factor in diabetic foot ulcer: progress and therapeutic prospects. Front Endocrinol (Lausanne). 2021;12:744868. doi:10.3389/fendo.2021.744868Yie J, Hecht R, Patel J, Stevens J, Wang W, Hawkins N et al. FGF21 N- and C-termini play different roles in receptor interaction and activation. FEBS Lett. 2009;583(1):19–24. doi:10.1016/j.febslet.2008.11.023Yie J, Hecht R, Patel J, Stevens J, Wang W, Hawkins N et al. FGF21 N- and C-termini play different roles in receptor interaction and activation. FEBS Lett. 2009;583(1):19–24. doi:10.1016/j.febslet.2008.11.023Ye M, Lu W, Wang X, Wang C, Abbruzzese JL, Liang G et al. FGF21-FGFR1 coordinates phospholipid homeostasis, lipid droplet function, and ER stress in obesity. Endocrinology. 2016;157(12):4754–4769. doi:10.1210/en.2016-1710Ye M, Lu W, Wang X, Wang C, Abbruzzese JL, Liang G et al. FGF21-FGFR1 coordinates phospholipid homeostasis, lipid droplet function, and ER stress in obesity. Endocrinology. 2016;157(12):4754–4769. doi:10.1210/en.2016-1710Raptis DD, Mantzoros CS, Polyzos SA. Fibroblast growth factor21 as a potential therapeutic target of nonalcoholic fatty liver disease. Ther Clin Risk Manag. 2023;19:77–96. doi:10.2147/TCRM.S352008Raptis DD, Mantzoros CS, Polyzos SA. Fibroblast growth factor21 as a potential therapeutic target of nonalcoholic fatty liver disease. Ther Clin Risk Manag. 2023;19:77–96. doi:10.2147/TCRM.S352008Wente W, Efanov AM, Brenner M, Kharitonenkov A, Köster A, Sandusky GE et al. Fibroblast growth factor21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes. 2006;55(9):2470–2478. doi:10.2337/db05-1435Wente W, Efanov AM, Brenner M, Kharitonenkov A, Köster A, Sandusky GE et al. Fibroblast growth factor21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes. 2006;55(9):2470–2478. doi:10.2337/db05-1435Al-Kuraishy HM, Al-Gareeb AI, Saad HM, Batiha GE. The potential effect of metformin on fibroblast growth factor 21 in type 2 diabetes mellitus (T2DM). Inflammopharmacology. 2023;31(4):1751–1760. doi:10.1007/s10787-023-01255-4Al-Kuraishy HM, Al-Gareeb AI, Saad HM, Batiha GE. The potential effect of metformin on fibroblast growth factor 21 in type 2 diabetes mellitus (T2DM). Inflammopharmacology. 2023;31(4):1751–1760. doi:10.1007/s10787-023-01255-4Qian Z, Zhang Y, Yang N, Nie H, Yang Z, Luo P et al. Close association between lifestyle and circulating FGF21 levels: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2022;13:984828. doi:10.3389/fendo.2022.984828Qian Z, Zhang Y, Yang N, Nie H, Yang Z, Luo P et al. Close association between lifestyle and circulating FGF21 levels: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2022;13:984828. doi:10.3389/fendo.2022.984828Wang WF, Li SM, Ren GP, Zheng W, Lu YJ, Yu YH et al. Recombinant murine fibroblast growth factor 21 ameliorates obesity-related inflammation in monosodium glutamate-induced obesity rats. Endocrine. 2015;49(1):119–129. doi:10.1007/s12020-014-0433-5Wang WF, Li SM, Ren GP, Zheng W, Lu YJ, Yu YH et al. Recombinant murine fibroblast growth factor 21 ameliorates obesity-related inflammation in monosodium glutamate-induced obesity rats. Endocrine. 2015;49(1):119–129. doi:10.1007/s12020-014-0433-5Tanajak P, Sa-Nguanmoo P, Wang X, Liang G, Li X, Jiang C et al. Fibroblast growth factor 21 (FGF21) therapy attenuates left ventricular dysfunction and metabolic disturbance by improving FGF21 sensitivity, cardiac mitochondrial redox homoeostasis and structural changes in pre-diabetic rats. Acta Physiol (Oxf). 2016;217(4):287–299. doi:10.1111/apha.12698Tanajak P, Sa-Nguanmoo P, Wang X, Liang G, Li X, Jiang C et al. Fibroblast growth factor 21 (FGF21) therapy attenuates left ventricular dysfunction and metabolic disturbance by improving FGF21 sensitivity, cardiac mitochondrial redox homoeostasis and structural changes in pre-diabetic rats. Acta Physiol (Oxf). 2016;217(4):287–299. doi:10.1111/apha.12698He JL, Zhao M, Xia JJ, Guan J, Liu Y, Wang LQ et al. FGF21 ameliorates the neurocontrol of blood pressure in the high fructose-drinking rats. Sci Rep. 2016;6:29582.He JL, Zhao M, Xia JJ, Guan J, Liu Y, Wang LQ et al. FGF21 ameliorates the neurocontrol of blood pressure in the high fructose-drinking rats. Sci Rep. 2016;6:29582.Guo Q, Xu L, Liu J, Li H, Sun H, Wu S et al. Fibroblast growth factor 21 reverses suppression of adiponectin expression via inhibiting endoplasmic reticulum stress in adipose tissue of obese mice. Exp Biol Med (Maywood). 2017;242(4):441–447. doi:10.1177/1535370216677354Guo Q, Xu L, Liu J, Li H, Sun H, Wu S et al. Fibroblast growth factor 21 reverses suppression of adiponectin expression via inhibiting endoplasmic reticulum stress in adipose tissue of obese mice. Exp Biol Med (Maywood). 2017;242(4):441–447. doi:10.1177/1535370216677354Laeger T, Baumeier C, Wilhelmi I, Würfel J, Kamitz A, SchürmannA. FGF21 improves glucose homeostasis in an obese diabetes-prone mouse model independent of body fat changes. Diabetologia. 2017;60(11):2274–2284. doi:10.1007/s00125-017-4389-xLaeger T, Baumeier C, Wilhelmi I, Würfel J, Kamitz A, SchürmannA. FGF21 improves glucose homeostasis in an obese diabetes-prone mouse model independent of body fat changes. Diabetologia. 2017;60(11):2274–2284. doi:10.1007/s00125-017-4389-xPan X, Shao Y, Wu F, Wang Y, Xiong R, Zheng J et al. FGF21 Prevents Angiotensin II-Induced Hypertension and Vascular Dysfunction by Activation of ACE2/Angiotensin-(1-7) Axis in Mice. Cell Metab. 2018;27(6):1323–1337.e5. doi:10.1016/j.cmet.2018.04.002Pan X, Shao Y, Wu F, Wang Y, Xiong R, Zheng J et al. FGF21 Prevents Angiotensin II-Induced Hypertension and Vascular Dysfunction by Activation of ACE2/Angiotensin-(1-7) Axis in Mice. Cell Metab. 2018;27(6):1323–1337.e5. doi:10.1016/j.cmet.2018.04.002Chen P, Xu B, Feng Y, Li KX, Liu Z, Sun X et al. FGF21 ameliorates essential hypertension of SHR via baroreflex afferent function. Brain Res Bull. 2020;154:9–20. doi:10.1016/j.brainresbull.2019.10.003Chen P, Xu B, Feng Y, Li KX, Liu Z, Sun X et al. FGF21 ameliorates essential hypertension of SHR via baroreflex afferent function. Brain Res Bull. 2020;154:9–20. doi:10.1016/j. brainresbull.2019.10.003Makarova E, Kazantseva A, Dubinina A, Denisova E, Jakovleva T, Balybina N et al. Fibroblast Growth Factor 21 (FGF21) administration sex-specifically affects blood insulin levels and liver steatosis in obese Ay Mice. Cells. 2021;10(12):3440. doi:10.3390/cells10123440Makarova E, Kazantseva A, Dubinina A, Denisova E, Jakovleva T, Balybina N et al. Fibroblast Growth Factor 21 (FGF21) administration sex-specifically affects blood insulin levels and liver steatosis in obese Ay Mice. Cells. 2021;10(12):3440. doi:10.3390/cells10123440Diener JL, Mowbray S, Huang WJ, Yowe D, Xu J, Caplan S et al. FGF21 normalizes plasma glucose in mouse models of type 1 diabetes and insulin receptor dysfunction. Endocrinology. 2021;162(9): bqab092. doi:10.1210/endocr/bqab092Diener JL, Mowbray S, Huang WJ, Yowe D, Xu J, Caplan S et al. FGF21 normalizes plasma glucose in mouse models of type 1 diabetes and insulin receptor dysfunction. Endocrinology. 2021;162(9): bqab092. doi:10.1210/endocr/bqab092Pan Q, Lin S, Li Y, Liu L, Li X, Gao X et al. Anovel GLP1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis. EBioMedicine. 2021;63:103202. doi:10.1016/j.ebiom.2020.103202Pan Q, Lin S, Li Y, Liu L, Li X, Gao X et al. Anovel GLP1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis. EBioMedicine. 2021;63:103202. doi:10.1016/j.ebiom.2020.103202Tanbek K, Yılmaz U, Gul M, Koç A, SandalS.Effects of central FGF21 infusion on the glucose homeostasis in rats (brainpancreas axis). Arch Physiol Biochem. 2023;130(5):515–522. doi :10.1080/13813455.2023.2166964Tanbek K, Yılmaz U, Gul M, Koç A, SandalS.Effects of central FGF21 infusion on the glucose homeostasis in rats (brainpancreas axis). Arch Physiol Biochem. 2023;130(5):515–522. doi :10.1080/13813455.2023.2166964Bartesaghi S, Wallenius K, Hovdal D, Liljeblad M, Wallin S, Dekker N et al. Subcutaneous delivery of FGF21 mRNA therapy reverses obesity, insulin resistance, and hepatic steatosis in diet-induced obese mice. Mol Ther Nucleic Acids. 2022;28:500– 513. doi:10.1016/j.omtn.2022.04.010Bartesaghi S, Wallenius K, Hovdal D, Liljeblad M, Wallin S, Dekker N et al. Subcutaneous delivery of FGF21 mRNA therapy reverses obesity, insulin resistance, and hepatic steatosis in diet-induced obese mice. Mol Ther Nucleic Acids. 2022;28:500– 513. doi:10.1016/j.omtn.2022.04.010Tillman EJ, Brock WJ, RolphT.Efruxifermin, a long-acting Fc-fusion FGF21 analogue, reduces body weight gain but does not increase sympathetic tone or urine volume in Sprague Dawley rats. British J Pharm. 2022;179(7):1384–1394. doi:10.1111/bph.15725Tillman EJ, Brock WJ, RolphT.Efruxifermin, a long-acting Fc-fusion FGF21 analogue, reduces body weight gain but does not increase sympathetic tone or urine volume in Sprague Dawley rats. British J Pharm. 2022;179(7):1384–1394. doi:10.1111/bph.15725Xu W, Gao X, Luo H, ChenY. FGF21 attenuates saltsensitive hypertension via regulating HNF4α/ACE2 axis in the hypothalamic paraventricular nucleus of mice. Clin Exp Hypertens. 2024;46(1):2361671. doi:10.1080/10641963.2024.2361671Xu W, Gao X, Luo H, ChenY. FGF21 attenuates saltsensitive hypertension via regulating HNF4α/ACE2 axis in the hypothalamic paraventricular nucleus of mice. Clin Exp Hypertens. 2024;46(1):2361671. doi:10.1080/10641963.2024.2361671Stanic S, Bardova K, Janovska P, Rossmeisl M, Kopecky J, ZouharP.Prolonged FGF21 treatment increases energy expenditure and induces weight loss in obese mice independently of UCP1 and adrenergic signaling. Biochem Pharmacol. 2024;221:116042. doi:10.1016/j.bcp.2024.116042Stanic S, Bardova K, Janovska P, Rossmeisl M, Kopecky J, ZouharP.Prolonged FGF21 treatment increases energy expenditure and induces weight loss in obese mice independently of UCP1 and adrenergic signaling. Biochem Pharmacol. 2024;221:116042. doi:10.1016/j.bcp.2024.116042Geng L, Lam KSL, XuA.The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic. Nat Rev Endocrinol. 2020;16(11):654–667. doi:10.1038/s41574-020-0386-0Geng L, Lam KSL, XuA.The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic. Nat Rev Endocrinol. 2020;16(11):654–667. doi:10.1038/s41574-020-0386-0Gaich G, Chien JY, Fu H, Glass LC, Deeg MA, Holland WL et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 2013;18(3):333– 340. doi:10.1016/j.cmet.2013.08.005Gaich G, Chien JY, Fu H, Glass LC, Deeg MA, Holland WL et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 2013;18(3):333– 340. doi:10.1016/j.cmet.2013.08.005Charles ED, Neuschwander-Tetri BA, Pablo Frias J, Kundu S, Luo Y, Tirucherai GS et al. Pegbelfermin (BMS986036), PEGylated FGF21, in patients with obesity and type 2 diabetes: results from a randomized phase 2 study. Obesity (Silver Spring). 2019;27(1):41–49. doi:10.1002/oby.22344Charles ED, Neuschwander-Tetri BA, Pablo Frias J, Kundu S, Luo Y, Tirucherai GS et al. Pegbelfermin (BMS986036), PEGylated FGF21, in patients with obesity and type 2 diabetes: results from a randomized phase 2 study. Obesity (Silver Spring). 2019;27(1):41–49. doi:10.1002/oby.22344Filtz A, Parihar S, Greenberg GS, Park CM, Scotti A, Lorenzatti D et al. New approaches to triglyceride reduction: Is there any hope left? Am J Prev Cardiol. 2024;18:100648. doi:10.1016/j.ajpc.2024.100648Filtz A, Parihar S, Greenberg GS, Park CM, Scotti A, Lorenzatti D et al. New approaches to triglyceride reduction: Is there any hope left? Am J Prev Cardiol. 2024;18:100648. doi:10.1016/j.ajpc.2024.100648Research study on whether a combination of 2 medicines (NNC0194 0499 and Semaglutide) works in people with NonAlcoholic SteatoHepatitis (NASH); ClinicalTrials.gov ID NCT05016882. https://clinicaltrials.gov/study/NCT05016882Research study on whether a combination of 2 medicines (NNC0194 0499 and Semaglutide) works in people with NonAlcoholic SteatoHepatitis (NASH); ClinicalTrials.gov ID NCT05016882. https://clinicaltrials.gov/study/NCT05016882Zhu L, Zhao H, Liu J, Cai H, Wu B, Liu Z et al. Dynamic folding modulation generates FGF21 variant against diabetes. EMBO Rep. 2021;22(1): e51352. doi:10.15252/embr.202051352Zhu L, Zhao H, Liu J, Cai H, Wu B, Liu Z et al. Dynamic folding modulation generates FGF21 variant against diabetes. EMBO Rep. 2021;22(1): e51352. doi:10.15252/embr.202051352Talukdar S, KharitonenkovA. FGF19 and FGF21: in NASH we trust. Mol Metab. 2021;46:101152. doi:10.1016/j.molmet.2020.101152Talukdar S, KharitonenkovA. FGF19 and FGF21: in NASH we trust. Mol Metab. 2021;46:101152. doi:10.1016/j.molmet.2020.101152

The authors declare that there are no conflicts of interest present.